HPV vaccination can effectively reduce the incidence of cervical cancer in women, and the nine-valent vaccine can prevent 90% of cervical cancer. The nine-valent vaccine is administered intramuscularly and the preferred site is the deltoid muscle of the upper arm, with a total of three doses of 0.5 mL per dose.
Women of vaccination age can choose to receive the first dose at any time, and the procedure of one dose in 0, 2 and 6 months is generally recommended, which means that the second dose will be given 2 months after the first dose, and the third dose will be given 4 months after the second dose.
The nine-valent vaccine is suitable for vaccination of women aged 16-26 years. Before receiving the HPV vaccine, it is important to note that
1. HPV screening is not required prior to vaccination.
2. Avoid using immunoglobulin or blood products for the first three months.
3. Inform your doctor of your medical history in advance, especially your past vaccination history and vaccine allergy history.
4. Postpone vaccination if you have acute severe febrile illness.
Common precautions after receiving the nine-valent vaccine.
1. After each completed vaccination, the vaccinated person needs to be strictly kept under observation for 30 minutes to prevent the occurrence of adverse reactions such as allergy, fever and nausea, and to facilitate timely treatment. Common adverse reactions at the vaccination site include local pain, swelling, erythema, fever, itching, and hard nodules. And a small number of people will have less common systemic adverse reactions after vaccination, such as diarrhea, headache, fever, dizziness, fatigue, muscle pain, arthralgia and gastrointestinal symptoms (nausea, vomiting, abdominal pain). Most of these adverse reactions are self-limiting and usually resolve spontaneously, and no special treatment is generally required.
2. If an allergic reaction occurs after vaccination, it is recommended to seek medical attention as soon as possible. Anti-allergy medication should be taken according to the doctor’s instruction. If the allergic reaction occurs after the first dose of vaccination, subsequent doses of vaccination should be suspended.
3. If adverse events such as cellulite, primary thrombocytopenic purpura, lymphadenopathy, acute disseminated encephalomyelitis (ADEM), dizziness, Guillain-Barre syndrome, hypersensitivity reactions, bronchospasm, urticaria, etc. occur after vaccination, prompt medical consultation is recommended.
4. Vaccination is not a substitute for routine cervical cancer screening or other measures to prevent HPV infection and sexually transmitted diseases, and regular cervical cancer screening should still be performed to prevent disease.
Reference.
[1] Liu YC, Sun LM, et al. Research progress of prophylactic nine-valent HPV vaccine[J]. Modern Oncology Medicine. 2017,25(5):827-829
[2]Wu BJ,Yang CJ.Research progress of HPV and its related vaccines[J]. Medical review.2018,24(4): 662-671
[3]Li Zhengxing,Sheng YH. A survey of nine-valent human papillomavirus vaccination among female students in a higher education institution in Yunnan [J]. Journal of practical medicine and technology. 2021,28(7): 847-850
[4] Du Jiayu, Li Qian. Safety study of nine-valent human papillomavirus vaccine[J]. Special Health, 2021,20: 95-96